USD 77.88
(1.79%)
Year | Operating Income | Operating Income Growth |
---|---|---|
2023 | -1.06 Billion USD | 98.32% |
2022 | -4.17 Billion USD | -3297.56% |
2021 | -123 Million USD | -121.21% |
2020 | 580 Million USD | -41.12% |
2019 | 985 Million USD | 11.55% |
2018 | 883 Million USD | 45.71% |
2017 | 606 Million USD | 3.23% |
2016 | 587.03 Million USD | -4.21% |
2015 | 612.84 Million USD | 19.07% |
2014 | 514.71 Million USD | 283.81% |
2013 | 134.1 Million USD | -33.2% |
2012 | 200.75 Million USD | 0.65% |
2011 | 199.46 Million USD | -5.76% |
2010 | 211.65 Million USD | 68.52% |
2009 | 125.59 Million USD | 56.1% |
2008 | 80.45 Million USD | 126.71% |
2007 | -301.21 Million USD | -896.6% |
2006 | 37.81 Million USD | 276.3% |
2005 | -21.44 Million USD | -289.03% |
2004 | -5.51 Million USD | 79.29% |
2003 | -26.62 Million USD | 36.39% |
2002 | -41.85 Million USD | -38.05% |
2001 | -30.31 Million USD | -30.49% |
2000 | -23.23 Million USD | -292.59% |
1999 | -5.91 Million USD | 0.0% |
Year | Operating Income | Operating Income Growth |
---|---|---|
2024 Q3 | 741 Million USD | 53.1% |
2024 Q1 | -59 Million USD | -3.51% |
2024 Q2 | 484 Million USD | 920.34% |
2023 Q2 | -88 Million USD | -37.5% |
2023 Q1 | -64 Million USD | 49.61% |
2023 FY | -70 Million USD | 98.32% |
2023 Q4 | -57 Million USD | 92.44% |
2023 Q3 | -754 Million USD | -756.82% |
2022 FY | -4.17 Billion USD | -3297.56% |
2022 Q4 | -127 Million USD | 96.53% |
2022 Q3 | -3.65 Billion USD | -531.61% |
2022 Q2 | -579 Million USD | -414.67% |
2022 Q1 | 184 Million USD | 348.78% |
2021 Q1 | 193 Million USD | 46.21% |
2021 Q2 | 187 Million USD | -3.11% |
2021 Q4 | 41 Million USD | 107.52% |
2021 Q3 | -545 Million USD | -391.44% |
2021 FY | -123 Million USD | -121.21% |
2020 Q3 | 162 Million USD | 68.75% |
2020 Q4 | 132 Million USD | -18.52% |
2020 FY | 580 Million USD | -41.12% |
2020 Q1 | 189 Million USD | -29.48% |
2020 Q2 | 96 Million USD | -49.21% |
2019 Q4 | 268 Million USD | -12.99% |
2019 FY | 985 Million USD | 11.55% |
2019 Q1 | 204 Million USD | 3.55% |
2019 Q2 | 205 Million USD | 0.49% |
2019 Q3 | 308 Million USD | 50.24% |
2018 FY | 883 Million USD | 45.71% |
2018 Q1 | 218 Million USD | -5.22% |
2018 Q2 | 227 Million USD | 4.13% |
2018 Q3 | 241 Million USD | 6.17% |
2018 Q4 | 197 Million USD | -18.26% |
2017 Q1 | 60 Million USD | -58.05% |
2017 FY | 606 Million USD | 3.23% |
2017 Q4 | 230 Million USD | 27.07% |
2017 Q3 | 181 Million USD | 26.57% |
2017 Q2 | 143 Million USD | 138.33% |
2016 FY | 587.03 Million USD | -4.21% |
2016 Q4 | 143.01 Million USD | -11.01% |
2016 Q1 | 121.44 Million USD | -15.66% |
2016 Q3 | 160.7 Million USD | -0.72% |
2016 Q2 | 161.86 Million USD | 33.29% |
2015 Q1 | 176.12 Million USD | -13.19% |
2015 Q4 | 144 Million USD | 2.29% |
2015 Q2 | 151.93 Million USD | -13.74% |
2015 Q3 | 140.78 Million USD | -7.34% |
2015 FY | 612.84 Million USD | 19.07% |
2014 Q4 | 202.88 Million USD | 69.79% |
2014 Q3 | 119.49 Million USD | 19.21% |
2014 Q2 | 100.23 Million USD | 8.84% |
2014 Q1 | 92.09 Million USD | 24.82% |
2014 FY | 514.71 Million USD | 283.81% |
2013 FY | 134.1 Million USD | -33.2% |
2013 Q4 | 73.78 Million USD | 62.29% |
2013 Q3 | 45.46 Million USD | -24.23% |
2013 Q2 | 60 Million USD | 232.91% |
2013 Q1 | -45.14 Million USD | -176.07% |
2012 Q4 | 59.34 Million USD | 21.58% |
2012 Q1 | 49.61 Million USD | 81.74% |
2012 Q3 | 48.81 Million USD | 13.57% |
2012 FY | 200.75 Million USD | 0.65% |
2012 Q2 | 42.98 Million USD | -13.37% |
2011 Q2 | 66.01 Million USD | -4.87% |
2011 Q1 | 69.38 Million USD | 1.05% |
2011 FY | 199.46 Million USD | -5.76% |
2011 Q4 | 27.29 Million USD | -25.75% |
2011 Q3 | 36.76 Million USD | -44.31% |
2010 FY | 211.65 Million USD | 68.52% |
2010 Q2 | 47.42 Million USD | 24.08% |
2010 Q3 | 57.33 Million USD | 20.89% |
2010 Q1 | 38.22 Million USD | 48.81% |
2010 Q4 | 68.66 Million USD | 19.76% |
2009 FY | 125.59 Million USD | 56.1% |
2009 Q1 | 34.5 Million USD | -4.35% |
2009 Q2 | 36.1 Million USD | 4.62% |
2009 Q4 | 25.68 Million USD | -12.33% |
2009 Q3 | 29.29 Million USD | -18.84% |
2008 FY | 80.45 Million USD | 126.71% |
2008 Q4 | 36.07 Million USD | 2248.7% |
2008 Q3 | 1.53 Million USD | -93.57% |
2008 Q2 | 23.87 Million USD | 25.81% |
2008 Q1 | 18.97 Million USD | 157.9% |
2007 Q2 | 12.25 Million USD | 104.13% |
2007 Q1 | -296.4 Million USD | -1888.13% |
2007 FY | -301.21 Million USD | -896.6% |
2007 Q4 | -32.76 Million USD | -308.58% |
2007 Q3 | 15.71 Million USD | 28.23% |
2006 Q4 | 16.57 Million USD | 8.67% |
2006 FY | 37.81 Million USD | 276.3% |
2006 Q1 | -541 Thousand USD | -3481.25% |
2006 Q2 | 6.52 Million USD | 1305.73% |
2006 Q3 | 15.25 Million USD | 133.85% |
2005 FY | -21.44 Million USD | -289.03% |
2005 Q2 | -18.54 Million USD | -1244.89% |
2005 Q3 | -1.53 Million USD | 91.71% |
2005 Q4 | 16 Thousand USD | 101.04% |
2005 Q1 | -1.37 Million USD | -145.66% |
2004 Q2 | -3.33 Million USD | 2.54% |
2004 Q4 | 3.02 Million USD | 269.66% |
2004 Q3 | -1.78 Million USD | 46.59% |
2004 Q1 | -3.42 Million USD | 9.95% |
2004 FY | -5.51 Million USD | 79.29% |
2003 Q2 | -8.49 Million USD | 5.54% |
2003 Q3 | -5.34 Million USD | 37.09% |
2003 Q4 | -3.79 Million USD | 28.9% |
2003 Q1 | -8.99 Million USD | 89.02% |
2003 FY | -26.62 Million USD | 36.39% |
2002 Q2 | -16.83 Million USD | -86.42% |
2002 Q4 | -81.88 Million USD | -844.34% |
2002 Q3 | 11 Million USD | 165.36% |
2002 Q1 | -9.02 Million USD | -1.08% |
2002 FY | -41.85 Million USD | -38.05% |
2001 FY | -30.31 Million USD | -30.49% |
2001 Q3 | -7.28 Million USD | 1.81% |
2001 Q2 | -7.41 Million USD | -10.79% |
2001 Q1 | -6.69 Million USD | 0.87% |
2001 Q4 | -8.93 Million USD | -22.69% |
2000 Q3 | -5.38 Million USD | 6.55% |
2000 Q4 | -6.75 Million USD | -25.43% |
2000 Q1 | -5.34 Million USD | 0.0% |
2000 FY | -23.23 Million USD | -292.59% |
2000 Q2 | -5.75 Million USD | -7.79% |
1999 FY | -5.91 Million USD | 0.0% |
Name | Operating Income | Operating Income Difference |
---|---|---|
Aclaris Therapeutics, Inc. | -97.35 Million USD | -998.021% |
Applied DNA Sciences, Inc. | -10.95 Million USD | -9659.625% |
Aspira Women's Health Inc. | -18.85 Million USD | -5570.486% |
Biodesix, Inc. | -41.34 Million USD | -2485.748% |
BioNexus Gene Lab Corp. | -2.59 Million USD | -41117.032% |
bioAffinity Technologies, Inc. | -7.97 Million USD | -13307.368% |
bioAffinity Technologies, Inc. | -7.97 Million USD | -13307.368% |
Bionano Genomics, Inc. | -215.24 Million USD | -396.643% |
CareDx, Inc | -101.9 Million USD | -949.068% |
Check-Cap Ltd. | -19.28 Million USD | -5442.593% |
Castle Biosciences, Inc. | -67.97 Million USD | -1472.591% |
DarioHealth Corp. | -56.18 Million USD | -1802.508% |
Exact Sciences Corporation | -215.01 Million USD | -397.182% |
Fulgent Genetics, Inc. | -72.69 Million USD | -1370.528% |
Guardant Health, Inc. | -564.72 Million USD | -89.296% |
ICON Public Limited Company | 956.15 Million USD | 211.802% |
IDEXX Laboratories, Inc. | 1.09 Billion USD | 197.436% |
Intelligent Bio Solutions Inc. | -10.28 Million USD | -10295.623% |
iSpecimen Inc. | -11.16 Million USD | -9470.835% |
Standard BioTools Inc. | -76.6 Million USD | -1295.561% |
MDxHealth SA | -27.32 Million USD | -3811.882% |
23andMe Holding Co. | -321.35 Million USD | -232.653% |
Medpace Holdings, Inc. | 336.82 Million USD | 417.375% |
Myriad Genetics, Inc. | -123.7 Million USD | -764.188% |
Mainz Biomed B.V. | -26.64 Million USD | -3912.058% |
ENDRA Life Sciences Inc. | -10.52 Million USD | -10060.887% |
NeoGenomics, Inc. | -107.73 Million USD | -892.24% |
Neogen Corporation | 58.66 Million USD | 1922.273% |
Inotiv, Inc. | -81.46 Million USD | -1212.301% |
Natera, Inc. | -446.24 Million USD | -139.555% |
OPKO Health, Inc. | -157.02 Million USD | -580.801% |
Psychemedics Corporation | -2.92 Million USD | -36497.056% |
Prenetics Global Limited | -52.51 Million USD | -1935.665% |
Prenetics Global Limited | -52.51 Million USD | -1935.665% |
Precipio, Inc. | -7.62 Million USD | -13928.871% |
Personalis, Inc. | -109.93 Million USD | -872.384% |
RadNet, Inc. | 98.69 Million USD | 1183.113% |
Sera Prognostics, Inc. | -39.82 Million USD | -2584.513% |
Sotera Health Company | 276.69 Million USD | 486.35% |
Neuronetics, Inc. | -30.55 Million USD | -3398.724% |
Star Equity Holdings, Inc. | -4.34 Million USD | -24497.331% |
Star Equity Holdings, Inc. | -4.34 Million USD | -24497.331% |
Trinity Biotech plc | -27.04 Million USD | -3852.671% |
Twist Bioscience Corporation | -220.83 Million USD | -384.081% |
Exagen Inc. | -22.83 Million USD | -4581.0% |